Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7MW3711
- Written by PR Newswire
SHANGHAI, Feb. 20, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its clinical trial application of B7-H3 targeting ADC (R&D code: 7MW3711) for advanced malignant solid tumor was approved by the U.S. Food and Drug Administration (FDA). 7MW3711 is developed by...
Read more: Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7MW3711














